Literature DB >> 30794966

Novel Trajectories for Identifying Asthma Phenotypes: A Longitudinal Study in Korean Asthma Cohort, COREA.

So Young Park1, Hee Won Jung2, Jae Moon Lee3, Bomi Shin3, Hyo Jung Kim3, Min-Hye Kim4, Woo-Jung Song3, Hyouk-Soo Kwon3, Jae-Woo Jung5, Sae-Hoon Kim6, Heung-Woo Park7, An-Soo Jang8, Yoon-Seok Chang6, You Sook Cho3, Young-Joo Cho4, Sang-Heon Cho7, Byoung Whui Choi5, Sungho Won9, Taesung Park10, Hee-Bom Moon3, Changsoo Kim11, Tae-Bum Kim12.   

Abstract

BACKGROUND: Unbiased cluster analysis has identified several asthma phenotypes. However, these phenotypes did not consistently predict disease prognosis and reflect temporal variability in airway inflammation.
OBJECTIVE: We aimed to identify longitudinal trajectories in terms of pulmonary function parameters and investigated whether the trajectories are associated with prognosis.
METHODS: Data were extracted from the Cohort for Reality and Evolution of Adult Asthma in Korea (COREA). Three-year pulmonary function test results were used to apply finite mixture models for group-based trajectory in 486 patients with eligible data set.
RESULTS: Two main sets of longitudinal trajectories were identified in terms of FEV1% predicted, and FEV1 variability. In the 4 trajectories determined with FEV1% predicted, the pulmonary function showed a consistent course in 4 stratified levels during 3 years of follow-up, which was associated with unexpected hospital visits and the use of steroid bursts due to exacerbation. The variability in pulmonary function showed 3 different patterns, and we found that higher blood and sputum eosinophil levels were associated with the higher variability in pulmonary function and more exacerbations.
CONCLUSIONS: Trajectory analysis is a novel method that provides longitudinal asthma phenotypes and aids in prediction of future risk of exacerbation. Further analysis is needed to validate the usefulness of these trajectories in an independent population.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asthma; Cluster analysis; Phenotypes; Trajectory

Year:  2019        PMID: 30794966     DOI: 10.1016/j.jaip.2019.02.011

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

1.  Relationship between age and bronchodilator response at diagnosis in adult-onset asthma.

Authors:  Minna Tommola; Ha-Kyeong Won; Pinja Ilmarinen; Heewon Jung; Leena E Tuomisto; Lauri Lehtimäki; Onni Niemelä; Tae-Bum Kim; Hannu Kankaanranta
Journal:  Respir Res       Date:  2020-07-13

2.  Activation of Group 2 Innate Lymphoid Cells via TL1A/DR3. A Solution to Corticosteroid Resistance?

Authors:  Chrysanthi Skevaki; Markus Weckmann
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

3.  Association of genetic variants of oxidative stress responsive kinase 1 (OXSR1) with asthma exacerbations in non-smoking asthmatics.

Authors:  Min-Hye Kim; Hun Soo Chang; Jong-Uk Lee; Ji-Su Shim; Jong-Sook Park; Young-Joo Cho; Choon-Sik Park
Journal:  BMC Pulm Med       Date:  2022-01-04       Impact factor: 3.317

4.  Soluble ACE2 and TMPRSS2 Levels in the Serum of Asthmatic Patients.

Authors:  Ji-Hyang Lee; Chae Eun Lee; Youngsang Yoo; Eunyong Shin; Jin An; Seo Young Park; Woo-Jung Song; Hyouk-Soo Kwon; You Sook Cho; Hee-Bom Moon; Tae-Bum Kim
Journal:  J Korean Med Sci       Date:  2022-02-28       Impact factor: 2.153

5.  Association Between Clinical Burden and Blood Eosinophil Counts in Asthma: Findings From a Korean Adult Asthma Cohort.

Authors:  Mi-Yeong Kim; Eun-Jung Jo; Sujeong Kim; Min-Hye Kim; Jae-Woo Jung; Joo-Hee Kim; Ji-Yong Moon; Jae-Woo Kwon; Jae-Hyun Lee; Chan Sun Park; Hyun Jung Jin; Yoo Seob Shin; Sae-Hoon Kim; Young-Joo Cho; Jung-Won Park; Sang-Heon Cho; Tae-Bum Kim; Hye-Kyung Park
Journal:  J Korean Med Sci       Date:  2022-02-21       Impact factor: 2.153

6.  Implication of Cluster Analysis in Childhood Asthma.

Authors:  Min Hye Kim; Tae Bum Kim
Journal:  Allergy Asthma Immunol Res       Date:  2021-01       Impact factor: 5.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.